Which developability parameters do you assess?

We assess key developability attributes such as stability (thermal/conformational), aggregation and self-association risk, solubility/formulation compatibility, charge-related heterogeneity (pI/variants), and sequence-based liabilities (e.g., deamidation/oxidation hotspots). Optional in silico immunogenicity risk screening can also be included.

Is the assessment based on in silico predictions, experimental assays, or a combination of both?

We use a combination of both. AI-powered in silico predictions help us identify and prioritize the most relevant risks upfront, so we can design and optimize the experimental assays accordingly—focusing on the right parameters, faster, with less material.

Can the assessment be performed on multiple antibody variants in parallel?

Yes — we can assess multiple antibody variants in parallel, enabling fast side-by-side comparison and selection of the most developable candidates.

What analytical and biophysical methods are included?

Depending on your needs, the package can include Bradford or UV280 (concentration), SDS-PAGE (purity/integrity), ELISA (antigen binding), SEC-HPLC (purity/solubility/aggregation), DLS (size & aggregation), nanoDSF (thermostability), and SPR or BLI (affinity).

What is the typical turnaround time?

Typical turnaround time is 2–3 weeks, depending on the number of variants and the selected assays.

Can the service be adapted depending on molecule format (IgG, VHH, bispecifics)?

Yes — the assessment can be adapted to all antibody formats (e.g., IgG, VHH, bispecifics) and across species, with a methodology tailored to the specific molecule type.

Do you provide clear go/no-go recommendations?

Yes — we deliver a detailed data report and provide clear go/no-go recommendations based on the results.

Can the results guide subsequent optimization steps such as humanization or affinity maturation?

Yes — the results can be used to guide downstream optimization, including humanization service and affinity maturation services, by highlighting the key developability risks and priorities to address.

Are your laboratories compliant with relevant quality standards (ISO, GMP-like)?

Yes — our laboratories operate under ISO-aligned quality standards, with GMP-like best practices applied where relevant to ensure robust traceability, documentation, and data integrity.

Can you support downstream optimization if developability issues are identified?

Yes — if developability risks are identified, we can support downstream optimization, using AI-guided predictions to design and prioritize the most effective sequence and engineering strategies.

Do you offer integrated packages combining discovery, engineering, and developability assessment?

Yes — we offer integrated end-to-end packages combining discovery, antibody engineering service, and developability assessment. Our teams work in synergy to support your program seamlessly from early candidate generation through final selection and optimization.

Antibody Developability Assessment Service

Characterizing your antibody to increase the probability it becomes a licensed biologic

2-3 weeks

7 tested parameters

100% Suitable for all antibody formats and species

Fast-track your antibody to market with developability-driven insights

Our developability evaluation highlights key liabilities upfront to secure the manufacturability of your antibody. Within 2–3 weeks, you can prevent late-stage developability issues and protect your project from costly delays. This early assessment helps you save resources and avoid time-consuming variant re-design.

By derisking development early, you accelerate your path toward a market-ready candidate.

Talk to our Experts

Make the right decisions early by identifying key optimization drivers

Assess 7 key developability parameters to make the right optimization decisions and support your recombinant antibody production services. At the end of the project, you receive a comprehensive report detailing all analyzed parameters and including a full risk assessment, with an optional 3D structural model.

A dedicated PhD-level expert supports you in interpreting the results and guides you toward the best strategic decisions for the next stages of your antibody development with the option to leverage our high throughput antibody production service.

3D rendering of Antibody Drug Conjugate molecules with cytotoxic payload

Developability for any antibody format and species

You benefit from high-quality scientific expertise and proven know-how in antibody development. Our antibody developability services are fully customized, even for complex projects: they adapt to all antibody formats and species.

Talk to our Experts

Need to improve the developability of your antibody? Discover AIxplore

Thanks to a fully transparent, AI-powered process, you can optimize your lead antibody variant and accelerate your path to the clinic.

Optimize your antibody with AIxplore

Make your antibody engineering project successful with our expertise

Our services work in full synergy, enabling seamless management of every stage of your project. A dedicated PhD-level expert oversees your entire custom antibody project, ensuring continuity and precision at every stage.

Bispecific antibody service

Antibody Drug Conjugate service

Car-T cell development platform

Stable Cell Line service

FAQ

We assess key developability attributes such as stability (thermal/conformational), aggregation and self-association risk, solubility/formulation compatibility, charge-related heterogeneity (pI/variants), and sequence-based liabilities (e.g., deamidation/oxidation hotspots). Optional in silico immunogenicity risk screening can also be included.